摘要：
Chronic myeloid leukemia (CML) is a hematopoietic myeloproliferative disorder. The Chinese prescription Danggui Longhui Wan (DGLHW) has been utilized in CML treatment, but its underlying mechanisms remain unclear. In this study, we gathered 794 constituents, 1249 drug targets, 1654 disease genes and 129 intersection genes. GO and KEGG were used to analyze the function of these genes. Compatibility of prescription study showed that monarch drug, minister drug, assistant and guide drug played a synergistic role in the treatment of CML. In addition, we obtained 20 hub genes and 12 key components. Molecular docking indicated that the main compounds and core proteins had good binding ability. The results of this study also showed that DGLHW might play a role in the treatment of CML by affecting MAPK, PI3K/AKT, FoxO and p53 signaling pathways.
Xuehan Ma, Qiulin Yan, Shaojiang Song, Guodong Yao. Network pharmacology to decipher the mechanism of Danggui Longhui Wan against chronic myeloid leukemia[J]. 亚洲传统医药, 2024, 19(4): 177-191.
Xuehan Ma, Qiulin Yan, Shaojiang Song, Guodong Yao. Network pharmacology to decipher the mechanism of Danggui Longhui Wan against chronic myeloid leukemia[J]. Asian Journal of Traditional Medicines, 2024, 19(4): 177-191.
